Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 211-220

  Matsui, Masanori ^a   Moriya, Osamu ^a   Abdel Aziz, Nada ^a   Matsuura, Yoshiharu ^b   Miyamura, Tatsuo ^c   Akatsuka, Toshitaka ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Dendritic cells; Hepatitis C virus; Recombinant adenovirus

Indexed keywords

ADENOVIRUS VECTOR; CORE PROTEIN; HEPATITIS C VACCINE; DNA VACCINE; HYBRID PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HEPATITIS C; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINIA VIRUS; VIRUS TITRATION; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; GENE VECTOR; GENETICS; HEPATITIS C VIRUS; IMMUNOLOGY; VACCINIA;

ADENOVIRIDAE; ANIMALS; CELL LINE; DENDRITIC CELLS; GENETIC VECTORS; HEPACIVIRUS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VACCINIA;

EID: 0037073541     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00460-7     Document Type: Article

References (47)

1. Choo Q.-L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
2. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander J.et al. The natural history of community-acquired hepatitis C in the United States: the sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med. 327:1992;1899-1905.
3. Saito I., Miyamura T., Ohbayashi A.et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA. 87:1990;6547-6549.
4. Wedemeyer H., Caselmann W.H., Manns M.P. Combination therapy of chronic hepatitis C: an important step but not the final goal. J Hepatol. 29:1998;1010-1014.
5. Cooper S., Erickson A.L., Adams E.J.et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 10:1999;439-449.
6. + T cells with viral clearance in acute hepatitis C. J Infect Dis. 181:2000;1528-1536.
7. Lechner F., Wong D.K.H., Dunbar P.R.et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 191:2000;1499-1512.
8. Takaki A., Wiese M., Maertens G.et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 6:2000;578-582.
9. Rehermann B., Chang K.-M., McHutchison J.G., Kokka R., Houghton M., Chisari F.V. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest. 98:1996;1432-1440.
10. Rehermann B., Chang K.-M., McHutchison J.et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol. 70:1996;7092-7102.
11. Banchereau J., Schuler-Thurner B., Palucka A.K., Schuler G. Dendritic cells as vectors for therapy. Cell. 106:2001;271-274.
12. Banchereau J., Briere F., Caux C.et al. Immunobiology of dendritic cells. Annu Rev Immunol. 18:2000;767-811.
13. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell. 106:2001;255-258.
14. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 20:2002;621-667.
15. Moriya O., Matsui M., Osorio M.et al. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine. 20:2002;789-796.
16. Zhong L., Granelli-Piperno A., Choi Y., Steinman R.M. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol. 29:1999;964-972.
17. Ralph P., Moore M.A., Nilsson K. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med. 143:1976;1528-1533.
18. Graham F.L., Smiley J., Russel W.C., Naim R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 36:1977;59-72.
19. Shirai M., Okada H., Nishioka M.et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol. 68:1994;3334-3342.
20. Makimura M., Miyake S., Akino N.et al. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine. 14:1996;28-34.
21. Lutz M.B., Kukutsch N., Ogilvie A.L.et al. An advanced culture method for generating large qualities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 223:1999;77-92.
22. Colligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Isolation of Murine Macrophages. Current Protocols in Immunology, vol. 3. New York: Wiley; 1994. p. 14.1.1-9.
23. Matsui M., Moots R.J., Warburton R.J.et al. Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. J Immunol. 154:1995;1088-1096.
24. Dubuisson J., Hsu H.H., Cheung R.G., Greenberg H.B., Russel D.G., Rice C.M. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and sindbis viruses. J Virol. 68:1994;6147-6160.
25. Matsui M., Machida S., Tomiyama H., Takiguchi M., Akatsuka T. Introduction of tapasin gene restores surface expression of HLA class I molecules, but not antigen presentation of an HIV envelope peptide in a hepatoma cell line. Biochem Biophys Res Commun. 285:2001;508-517.
26. + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest. 102:1998;2072-2081.
27. Wedemeyer H., Gagneten S., Davis A., Bartenschlager R., Feinstone S., Rehermann B. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse mode. Gastroenterology. 121:2001;1158-1166.
28. Erickson A.L., Kimura Y., Igarashi S.et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 15:2001;883-895.
29. Liu Y.-J. Dendritic cell subsets and lineages. Cell. 106:2001;259-262.
30. Brossart P., Goldrath A.W., Butz E.A., Martin S., Bevan M.J. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol. 158:1997;3270-3276.
31. Song W., Kong H.-L., Carpenter H.et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med. 186:1997;1247-1256.
32. Butterfield L.H., Jilani S.M., Chakraborty N.G.et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 161:1998;5607-5613.
33. Kaplan J.M., Yu Q., Piraino S.T., Pennington S.E., Shankara S., Woodworth L.A.et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol. 163:1999;699-707.
34. Gahn B., Siller-Lopez F., Pirooz A.D.et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer. 93:2001;706-713.
35. Specht J.M., Wang G., Do M.T.et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med. 186:1997;1213-1221.
36. Bronte V., Carroll M.W., Goletz T.J.et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA. 94:1997;3183-3188.
37. Chiriva-Internati M., Liu Y., Salati E.et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol. 32:2002;30-38.
38. Motta I., Andre F., Lim A.et al. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol. 167:2001;1795-1802.
39. Engelmayer J., Larsson M., Subklewe M.et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol. 163:1999;6762-6768.
40. + T-cell responses from chronically infected individuals. J Virol. 75:2001;2142-2153.
41. Bruna-Romero O., Lasarte J.J., Wilkinson G.et al. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology. 25:1997;470-477.
42. Ahlers J.D., Belyakov I.M., Matsui S., Berzofsky J.A. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int Immunol. 13:2001;897-908.
43. Delby M.A., Alexander-Miller M.A., Tse R., Berzofsky J.A. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol. 166:2001;1690-1697.
44. Katz E., Wolffe E.J., Moss B. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J Virol. 71:1997;3178-3187.
45. Major M.E., Feinstone S.M. The molecular virology of hepatitis C. Hepatology. 25:1997;1527-1538.
46. Harris N., Buller R.M., Karupiah G. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J Virol. 69:1995;910-915.
47. Forns X., Payette P.J., Ma X.et al. Vaccination of Chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hapatology. 32:2000;618-625.